Cll leukaemia treatment

‍

The European Partnership for Personalised Medicine (EP PerMed), supported by the European Union under Horizon Europe, in launched its first joint transnational call (JTC) for proposals on “Identificationor Validation of Targets for Personalised Medicine Approaches (PMTargets)”.

Altogether, 45 million Euro were made available through this call.

The project CLL-OUTCOME, Chronic lymphocyticleukemia: Improving survival and quality of life, has now received an allocation of 18 million NOK ( mEuro) over three years.

We congratulate Sigrid Skånland, project leader at the Institute for Cancer Research, OUH and researcher in functional precision oncology in MATRIX. CLL-OUTCOME is led by Sigrid Skånland and Oslo University Hospital (OUH), and the project has a total of 7 partners.

The main focus of the project is to tailor the treatment of patients with CLL (chronic lymphocytic leukemia) to